OLD Point Trust & Financial Services N A Sells 980 Shares of Pfizer Inc. (NYSE:PFE)

OLD Point Trust & Financial Services N A trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 65,073 shares of the biopharmaceutical company’s stock after selling 980 shares during the period. OLD Point Trust & Financial Services N A’s holdings in Pfizer were worth $1,726,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the fourth quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer in the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Trading Down 0.5 %

Shares of PFE opened at $26.18 on Thursday. The stock has a market capitalization of $148.35 billion, a PE ratio of 18.57, a P/E/G ratio of 0.64 and a beta of 0.61. The company’s fifty day moving average is $26.19 and its 200 day moving average is $27.08. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.